Bacillus Calmette-Guerin Live Antigen, Unspecified Substrain
Multiple Sclerosis
Explore 182 assets in Multiple Sclerosis →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
S. Andrea Hospital
Modality
vaccine
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03888924CT.gov Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Multiple Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bacillus Calmette-Guerin Live Antigen, Unspecified Substrain (this asset) | S. Andrea Hospital | P2 | CCC · 48 |
| Nabiximols | Jazz Pharmaceuticals | P4 | BBB |
| Fampridine | MGH Institute of Health Professions | P4 | BBB |
| Ocrelizumab | Polpharma Biologics International AG | P4 | BBB |
| Cladribine | University Hospital, Strasbourg, France | P4 | BBB |
| Teriflunomide | Sanofi | P4 | BBB |
| Fingolimod | Biogen | P4 | BB |
| Natalizumab | Biogen | P4 | BB |
| Interferon ?1 (Human Fibroblast Protein Moiety) | Bayer | P4 | BB |
+42 more in the Multiple Sclerosis cohort
Other indications for Bacillus Calmette-Guerin Live Antigen, Unspecified Substrain
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Alzheimer Disease | — | P2 | BB · 64 |
| Metastatic Melanoma | — | P2/3 | B · 61 |
| Superficial Urinary Bladder Carcinoma | — | P3 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bacillus Calmette-Guerin Live Antigen, Unspecified Substrain in Multiple Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bacillus-calmette-guerin-live-antigen-unspecified-substrain-multiple-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →